Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Keyamura, Yuka ^a,b   Nagano, Chifumi ^a   Kohashi, Masayuki ^a   Niimi, Manabu ^a   Nozako, Masanori ^a   Koyama, Takashi ^a   Yasufuku, Reiko ^a   Imaizumi, Ayako ^a   Itabe, Hiroyuki ^b   Yoshikawa, Tomohiro ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ANTIOXIDANT; BIOLOGICAL MARKER; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IN VITRO STUDY; LIPID OXIDATION; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PROTEIN BLOOD LEVEL; TREATMENT DURATION; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG POTENTIATION; METABOLISM; RABBIT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; DRUG SYNERGISM; HEPTANOIC ACIDS; PROBUCOL; PYRROLES; RABBITS;

EID: 84901045045     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096929     Document Type: Article

References (36)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
2. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681.
3. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, et al. (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358: 1431-1443. (Pubitemid 351482735)
4. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809.
5. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924. (Pubitemid 19101597)
6. Witzum JL, Sterinberg D (1991) Role of oxidized low dencity lipoprotein in atherogenesis. J Clin Invest 88: 1785-1792.
7. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D (1986) Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77: 641-644. (Pubitemid 16037669)
8. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, et al. (1987) Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84: 5928-5931.
9. Sasahara M, Raines EW, Chait A, Carew TE, Steinberg D, et al. (1994) Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol: I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 94: 155-164.
10. Yoshikawa T, Mitani K, Kotosai K, Nozako M, Miyakoda G, et al. (2008) Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. Horm Metab Res 40: 473-478.
11. Yoshikawa T, Shimano H, Chen Z, Ishibashi S, Yamada N (2001) Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice. Horm Metab Res 33: 472-479. (Pubitemid 32881894)
12. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hådell K, et al. (1994) The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 74: 875-883. (Pubitemid 24340308)
13. Yamashita S, Matsuzawa Y (2009) Where are we with probucol: A new life for an old drug? Atherosclerosis 207: 16-23.
14. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, et al. (2002) Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 39: 610-616. (Pubitemid 34158156)
15. Yamashita S, Bujo H, Arai H, Harada-Shiba M, Matsui S, et al. (2008) Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 15: 292-303.
16. Kasai T, Miyauchi K, Kubota N, Kajimoto K, Amano A, et al. (2012) Probucol therapy improves long-term (.10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis 220: 463-469.
17. Bräsen JH, Harsch M, Niendorf A (1998) Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet. Virchows Arch 432: 557-562. (Pubitemid 28297564)
18. Ge CJ, Lü SZ, Feng LX, Huo Y, Song XT, et al. (2012) Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion. Chin Med J (Engl) 125: 2472-2476.
19. Zhou Q, Liao JK (2010) Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J 74: 818-826.
20. Hatch FT, Lee RS (1968) Practical method for plasma lipoprotein analysis. Adv Lipid Res 6: 1-68.
21. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, et al. (1994) A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholine and polypeptides. J Biol Chem 269: 15274-15279.
22. Kato R, Mori C, Kitazato K, Arata S, Obama T, et al. (2009) Transient increase in plasma oxidized LDL during the progression of atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 29: 33-39.
23. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, et al. (2004) Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 89: 4963-4971. (Pubitemid 39391435)
24. Inagaki M, Nakagawa-Toyama Y, Nishida M, Nakatani K, Nakaoka H, et al. (2012) Effect of Probucol on Antioxidant Properties of HDL in Patients with Heterozygous Familial Hypercholesterolemia. J Atheroscler Thromb 19: 643-656.
25. Niimi M, Keyamura Y, Nozako M, Koyama T, Kohashi M, et al. (2013) Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. Lipids Health Dis 12: 166.
26. Yu Q, Li Y, Wang Y, Zhao S, Yang P, et al. (2012) C-reactive protein levels are associated with the progression of atherosclerotic lesions in rabbits. Histol Histopathol 27: 529-535.
27. Steinberg G (1986) Studies on the mechanism of action of probucol. Am J Cardiol 57: 16H-21H.
28. Tawara K, Tomikawa M, Abiko Y (1986) Mode of action of probucol in reducing serum cholesterol in mice. Jpn J Pharmacol 40: 123-133. (Pubitemid 16180392)
29. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2011) HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8: 222-232.
30. Itabe H (2009) Oxidative modification of LDL: its pathological role in atherosclerosis. Clin Rev Allergy Immunol 37: 4-11.
31. Wu BJ, Kathir K, Witting PK, Beck K, Choy K, et al. (2006) Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med 203: 1117-1127.
32. Itoh S, Umemoto S, Hiromoto M, Toma Y, Tomochika Y, et al. (2002) Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. Circulation 105: 2288-2295. (Pubitemid 34535340)
33. Takeshita S, Inoue N, Gao D, Rikitake Y, Kawashima S, et al. (2000) Lysophosphatidylcholine enhances superoxide anions production via endothelial NADH/NADPH oxidase. J Atheroscler Thromb 7: 238-246.
34. Schmitz G, Ruebsaamen K (2010) Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 208: 10-18.
35. Moghadasian MH, McManus BM, Godin DV, Rodrigues B, Frohlich JJ (1999) Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation 99: 1733-1739. (Pubitemid 29162487)
36. Xu Z, Azordegan N, Zhao Z, Le K, Othman RA, et al. (2009) Pro-atherogenic effects of probucol in apo E-KO mice may be mediated through alterations in immune system: Parallel alterations in gene expression in the aorta and liver. Atherosclerosis 206: 427-433.